Azimuth Capital Management LLC raised its position in Allergan PLC. (NYSE:AGN) by 1.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,291 shares of the company’s stock after buying an additional 225 shares during the period. Azimuth Capital Management LLC’s holdings in Allergan PLC. were worth $3,175,000 at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in the company. Crestwood Advisors Group LLC acquired a new position in shares of Allergan PLC. during the first quarter worth about $103,000. Feltz Wealth PLAN Inc. acquired a new position in shares of Allergan PLC. during the first quarter worth about $107,000. Enterprise Financial Services Corp raised its position in shares of Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock worth $110,000 after buying an additional 178 shares during the period. JNBA Financial Advisors raised its position in shares of Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after buying an additional 12 shares during the period. Finally, Webster Bank N. A. raised its position in shares of Allergan PLC. by 31.0% in the first quarter. Webster Bank N. A. now owns 520 shares of the company’s stock worth $124,000 after buying an additional 123 shares during the period. Institutional investors and hedge funds own 83.63% of the company’s stock.
Allergan PLC. (AGN) traded down 0.35% on Friday, hitting $223.99. 2,006,235 shares of the stock were exchanged. The company’s 50-day moving average is $243.31 and its 200-day moving average is $238.68. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The company has a market cap of $74.88 billion, a PE ratio of 6.82 and a beta of 1.16.
Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion during the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period in the prior year, the business earned $3.35 EPS. On average, analysts predict that Allergan PLC. will post $16.27 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be paid a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.25%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio is currently 9.95%.
WARNING: “Azimuth Capital Management LLC Purchases 225 Shares of Allergan PLC. (AGN)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.com-unik.info/2017/08/19/azimuth-capital-management-llc-acquires-225-shares-of-allergan-plc-agn-updated-updated-updated.html.
AGN has been the topic of a number of research reports. Royal Bank Of Canada set a $284.00 target price on shares of Allergan PLC. and gave the stock a “buy” rating in a research report on Monday, June 12th. Mizuho lowered their price objective on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating on the stock in a research report on Friday, June 9th. Cowen and Company set a $400.00 price objective on shares of Allergan PLC. and gave the company a “buy” rating in a research report on Thursday, June 8th. UBS AG reiterated a “buy” rating and issued a $275.00 price objective on shares of Allergan PLC. in a research report on Monday, May 15th. Finally, Citigroup Inc. lifted their price objective on shares of Allergan PLC. to $261.00 and gave the company a “buy” rating in a research report on Monday, April 24th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $275.49.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
What are top analysts saying about Allergan PLC.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Allergan PLC. and related companies.